• Mashup Score: 0
    Quantifying the Value of the Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance - 1 year(s) ago

    PURPOSE Molecular tumor boards (MTBs) provide interventions that assist the patient’s primary oncologist’s interpretation and application of precision oncology and avoid clinical and financial toxicities of prescribing inappropriate targeted therapy. In this article, we describe a novel method for illustrating MTBs value and recommendation discordance rate and report associated drug cost…

    Source: JCO Precision Oncology
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of mtmdphd
      mtmdphd

      Quantifying the Value of Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance [Oct 20, 2022] @mkwalters305 @JimW9200 @antonyruggeri @mullane_michael Hunt, Wilson, Ramczyk, @mtmdphd @JCOPO_ASCO https://t.co/OORXChBGjx #PrecisionMedicine #hpeonc https://t.co/AyS25R24uM

  • Mashup Score: 0
    Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures - 1 year(s) ago

    PURPOSE Biliary tract cancers (BTCs) are aggressive cancers that carry a poor prognosis. An enhanced understanding of the immune landscape of anatomically and molecularly defined subsets of BTC may improve patient selection for immunotherapy and inform immune-based combination treatment strategies. METHODS We analyzed deidentified clinical, genomic, and transcriptomic data from the Tempus…

    Source: JCO Precision Oncology
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of mtmdphd
      mtmdphd

      Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures [Jun 8, 2022] @kabir_mody et al. @MarkYarchoan @JCOPO_ASCO https://t.co/IN6UsL5Rll #hpbcsm #PrecisionMedicine

  • Mashup Score: 0
    Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers - 1 year(s) ago

    PURPOSE Circulating tumor DNA (ctDNA) analyses allow for postoperative risk stratification in patients with curatively treated colon and breast cancers. Use of ctDNA in esophagogastric cancers (EGC) is less characterized and could identify high-risk patients who have been treated with curative intent. METHODS In this retrospective analysis of real-world data, ctDNA levels were analyzed in the…

    Source: JCO Precision Oncology
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of pashtoonkasi
      pashtoonkasi

      Building on our @JCOPO_ASCO publication, I have this patient with stage-IV HER2➕➕➕gastric cancer with an exceptional response who made it to surgery. However, never turned #ctDNA➖. High risk path. Gave T-DXd “2nd” line➡️➖right away & on a holiday. 📝https://t.co/LIYFNr4dH1 https://t.co/05VHvdvF9E

  • Mashup Score: 0
    Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers - 1 year(s) ago

    PURPOSE Circulating tumor DNA (ctDNA) analyses allow for postoperative risk stratification in patients with curatively treated colon and breast cancers. Use of ctDNA in esophagogastric cancers (EGC) is less characterized and could identify high-risk patients who have been treated with curative intent. METHODS In this retrospective analysis of real-world data, ctDNA levels were analyzed in the…

    Source: JCO Precision Oncology
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of pashtoonkasi
      pashtoonkasi

      Sounds like we were popular @JCOPO_ASCO @ASCO👇🏾. Hanging out with the cool kids. @KlempnerSam @BHuffmanMD @DocCatenacci @JoeChaoMD @gregorybotta @DayyaniFarshid 🩸#ctDNA is here to stay. @OncoAlert #LiquidBiopsies Here’s the link to the full paper: https://t.co/LIYFNqMCPt https://t.co/4y7GHyJ6qS https://t.co/3kAPSWPtYF

  • Mashup Score: 0
    Use of Erdafitinib in FGFR3-Mutated Recurrent Respiratory Papillomatosis - 1 year(s) ago

    Conception and design: Vincent Yeung, Rebecca Krochmal, Charu Aggarwal, Stephen V. Liu, Chul KimAdministrative support: Chul KimProvision of study materials or patients: Chul KimCollection and assembly of data: Vincent Yeung, Nazaneen N. Grant, Nishant Gandhi, Stephen V. Liu, Chul KimData analysis and interpretation: Vincent Yeung, Paul Sackstein, Rebecca Krochmal, Nishant Gandhi, Balazs Halmos,…

    Source: JCO Precision Oncology
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of chulkimMD
      chulkimMD

      Recurrent respiratory papillomatosis (#RRP) is generally a benign disease but a subset exhibits aggressive course with lung involvement Role of targeted therapy is not well defined Here we describe use of erdafitinib for FGFR3-mutated RRP! https://t.co/jvUmrl8ogF @JCOPO_ASCO https://t.co/ZrrROEF0MQ

  • Mashup Score: 1
    Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care - 1 year(s) ago

    PURPOSE The combination of whole-genome and transcriptome sequencing (WGTS) is expected to transform diagnosis and treatment for patients with cancer. WGTS is a comprehensive precision diagnostic test that is starting to replace the standard of care for oncology molecular testing in health care systems around the world; however, the implementation and widescale adoption of this best-in-class…

    Source: JCO Precision Oncology
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ESchattner
      ESchattner

      "Mounting evidence shows that WGTS [Whole-Genome and Transcriptome Sequencing] enables improved diagnosis over existing clinical tests" in #oncology. But is it feasible to study all cancer in such molecular detail? @JCOPO_ASCO https://t.co/eQVXogbLQv? #PathTwitter #PrecisionOnc https://t.co/bA7fk6UBCv

  • Mashup Score: 0
    Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board - 1 year(s) ago

    Purpose Precision oncology develops and implements evidence-based personalized therapies that are based on specific genetic targets within each tumor. However, a major challenge that remains is the provision of a standardized, up-to-date, and evidenced-based precision medicine initiative across a geographic region. Materials and Methods We developed a statewide molecular tumor board that…

    Source: JCO Precision Oncology
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of mtmdphd
      mtmdphd

      Implementation & Utility of an Integrated Academic-Community #PrecisionMedicine MTB [Jul 5, 2017] @meburkard et al. @JCOPO_ASCO https://t.co/HOWIx826Lm https://t.co/oOQ6ZUrefK

Load More